Biote to Participate at Upcoming Investor Conferences
-
On
June 6, 2023 ,Terry Weber , Biote’s Chief Executive Officer, andSamar Kamdar , Biote’s Chief Financial Officer, will present at10:40 AM ET at TD Cowen’s 7th Annual Future of theConsumer Conference inNew York, NY .Marc Beer , Biote’s Executive Chairman, will joinMs. Weber andMr. Kamdar in hosting investor meetings at the conference. -
On
June 8, 2023 ,Ms. Weber andMr. Kamdar will present at2:00 PM ET at theJefferies Healthcare Conference inNew York, NY .Mr. Beer will joinMs. Weber andMr. Kamdar in hosting investor meetings at the conference. A live webcast of the presentation will be available on Biote’s Investor Relations website here. The webcast replay will be available for 90 days following the live event on Biote’s Investor Relations website here.
About
Forward-Looking Statements
This press release contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Some of the forward-looking statements can be identified by the use of forward-looking words. Statements that are not historical in nature, including the words “may,” “can,” “should,” “will,” “estimate,” “plan,” “project,” “forecast,” “intend,” “expect,” “hope,” “anticipate,” “believe,” “seek,” “target,” “continue,” “could,” “might,” “ongoing,” “potential,” “predict,” “would” and other similar expressions, are intended to identify forward-looking statements. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual results or developments to differ materially from those expressed or implied by such forward-looking statements, including but not limited to: the success of our dietary supplements to attain significant market acceptance among clinics, practitioners and their patients; our customers’ reliance on certain third parties to support the manufacturing of bio-identical hormones for prescribers; our and our customers’ sensitivity to regulatory, economic, environmental and competitive conditions in certain geographic regions; our ability to increase the use by practitioners and clinics of the Biote Method at the rate that we anticipate or at all; our ability to grow our business; the significant competition we face in our industry; our limited operating history; our ability to protect our intellectual property; the heavy regulatory oversight in our industry; changes in applicable laws or regulations; the inability to profitably expand in existing markets and into new markets; the possibility that we may be adversely impacted by other economic, business and/or competitive factors, including recent bank failures; and future exchange and interest rates. The foregoing list of factors is not exhaustive. You should carefully consider the foregoing factors and the other risks and uncertainties described in the “Risk Factors” section of Biote’s Quarterly Report on Form 10-Q for the fiscal quarter ended
View source version on businesswire.com: https://www.businesswire.com/news/home/20230531005097/en/
Media Contact
Press@biote.com
Investor Contact
IR@biote.com
Source: biote Corp.